Inovio Pharmaceuticals, Inc. (INO)

NASDAQ: INO · IEX Real-Time Price · USD
0.394
+0.007 (1.86%)
Sep 22, 2023, 4:00 PM EDT - Market closed
1.86%
Market Cap 105.57M
Revenue (ttm) 9.62M
Net Income (ttm) -168.43M
Shares Out 268.08M
EPS (ttm) -0.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,743
Open 0.394
Previous Close 0.387
Day's Range 0.375 - 0.394
52-Week Range 0.375 - 2.610
Beta 0.97
Analysts Hold
Price Target 2.00 (+407.87%)
Earnings Date Nov 7, 2023

About INO

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medic... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 1998
Employees 135
Stock Exchange NASDAQ
Ticker Symbol INO
Full Company Profile

Financial Performance

In 2022, INO's revenue was $10.26 million, an increase of 478.23% compared to the previous year's $1.77 million. Losses were -$279.82 million, -7.85% less than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for INO stock is "Hold." The 12-month stock price forecast is $2.0, which is an increase of 407.87% from the latest price.

Price Target
$2.0
(407.87% upside)
Analyst Consensus: Hold
Stock Forecasts

News

INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

• Designation based on clinical evidence indicating INO-3107 may demonstrate substantial improvement over existing therapies • First Breakthrough Therapy designation for an INOVIO DNA medicine candida...

18 days ago - PRNewsWire

INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference

PLYMOUTH MEETING, Pa. , Aug. 29, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel...

27 days ago - PRNewsWire

INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update

Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Commission in second quarter Scaling res...

6 weeks ago - PRNewsWire

INOVIO Reports Inducement Grants Under Inducement Plan

PLYMOUTH MEETING, Pa. , Aug. 4, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-asso...

7 weeks ago - PRNewsWire

INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023

PLYMOUTH MEETING, Pa. , July 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...

2 months ago - PRNewsWire

INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Plymouth Meeting, Pa., June 23, 2023 (GLOBE NEWSWIRE) -- INOVIO (NASDAQ:INO) has released the following pursuant to an order of the UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA:

3 months ago - GlobeNewsWire

INOVIO to Present at the 2023 Jefferies Healthcare Conference

PLYMOUTH MEETING, Pa. , May 25, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel...

4 months ago - PRNewsWire

INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

PLYMOUTH MEETING, Pa. , May 23, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela...

4 months ago - PRNewsWire

INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights

Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed 10 of the 11 (91%) patients saw a reduction in surgi...

4 months ago - PRNewsWire

New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023

Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles) Data indicates INO-3107 was well tolerated and has the potential to provide cl...

5 months ago - PRNewsWire

INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference

PLYMOUTH MEETING, Pa. , May 5, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela...

5 months ago - PRNewsWire

INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023

PLYMOUTH MEETING, Pa. , April 28, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-a...

5 months ago - PRNewsWire

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023

Safety and Immunological data from both cohorts of the recently completed Phase 1/2 trial will be presented on May 5 th PLYMOUTH MEETING, Pa. , April 27, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a b...

5 months ago - PRNewsWire

European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107

European Commission to review and make a final decision, expected late May 2023 PLYMOUTH MEETING, Pa. , April 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developi...

5 months ago - PRNewsWire

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023

PLYMOUTH MEETING, Pa., April 12, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...

5 months ago - PRNewsWire

INOVIO Reports Inducement Grant Under Inducement Plan

PLYMOUTH MEETING, Pa. , April 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-as...

6 months ago - PRNewsWire

INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference

PLYMOUTH MEETING, Pa. , March 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel...

7 months ago - PRNewsWire

INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights

Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions (HSIL) Trial results did not meet the prima...

7 months ago - PRNewsWire

INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

10 of 11 patients (91%) had a reduction in number of surgical interventions, measured from Day 0 to one year following initial treatment; 4 of the 10 patients did not need any surgery Treatment with I...

7 months ago - PRNewsWire

INOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023

PLYMOUTH MEETING, Pa. , Feb. 15, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...

7 months ago - PRNewsWire

INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)

INO-4201 found to be well-tolerated in the trial Humoral responses were boosted in 100% (36 of 36) of treated participants PLYMOUTH MEETING, Pa. , Feb. 2, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a b...

8 months ago - PRNewsWire

INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates

Cost-saving measures include 11% headcount reduction Annual savings expected to be approximately $4.3 million Data readouts expected in first quarter of 2023 for key programs including INO-3107 for RR...

8 months ago - PRNewsWire

INOVIO Provides an Update on Lassa Fever and MERS Programs

PLYMOUTH MEETING, Pa. , Nov. 17, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious disease...

11 months ago - PRNewsWire

INOVIO Reports Financial Results and Highlights for the Third Quarter 2022

Announced positive interim data for INO-3107 as a potential first-in-class treatment for Recurrent Respiratory Papillomatosis Advanced strategy to focus on developing candidates that have the greatest...

11 months ago - PRNewsWire

INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800

PLYMOUTH MEETING, Pa. , Oct. 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases...

11 months ago - PRNewsWire